Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been assigned a consensus recommendation of "Hold" from the nine research firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $10.00.

A number of equities research analysts have commented on ZNTL shares. Guggenheim reduced their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday, November 15th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ZNTL. China Universal Asset Management Co. Ltd. raised its position in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock valued at $50,000 after buying an additional 5,333 shares during the last quarter. Carson Advisory Inc. lifted its position in shares of Zentalis Pharmaceuticals by 55.8% during the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company's stock valued at $90,000 after purchasing an additional 8,800 shares in the last quarter. Anfield Capital Management LLC purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $40,000. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals in the 3rd quarter worth about $37,000. Finally, Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at about $37,000.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock traded up $0.04 on Tuesday, hitting $3.22. 421,099 shares of the company's stock traded hands, compared to its average volume of 1,301,856. The company has a market capitalization of $229.47 million, a price-to-earnings ratio of -1.29 and a beta of 1.84. The company has a fifty day moving average of $3.33 and a two-hundred day moving average of $3.84. Zentalis Pharmaceuticals has a one year low of $2.66 and a one year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.